Variability of Sulfotransferase Activity in Humans: an Approach to Improve Predictive Drug Response Part II: Analysis of Interindividual Variation in Hypertensive Patients

An open-label, single center, nonrandomized clinical study in hypertensive patients, with intervention, over a 5-week period. After written informed consent, subjects will undergo screening evaluations, including blood and urine sampling (Visit 1). After visit 1, subjects who meet the selection criteria will enter a run-in period where they will receive paracetamol 1g tablet and collect blood and urine samples 2 hours afterwards (visit 2). A final visit for safety assessment will take place at week 5 (visit 3). Blood and urine samples will be used to quantify paracetamol and its metabolites.